{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:07:24Z","timestamp":1787616444677,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The evolution of novel SARS-CoV-2 variants significantly affects vaccine effectiveness. While these effects can only be studied retrospectively, neutralizing antibody titers are most used as correlates of protection. However, studies assessing neutralizing antibody titers often show heterogeneous data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To address this, we investigated assay variance and identified virus infection time and dose as factors affecting assay robustness. We next measured neutralization against Omicron sub-variants in cohorts with hybrid or vaccine induced immunity, identifying a gradient of immune escape potential. To evaluate the effect of individual mutations on this immune escape potential of Omicron variants, we systematically assessed the effect of each individual mutation specific to Omicron BA.1, BA.2, BA.2.12.1, and BA.4\/5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We cloned a library of pseudo-viruses expressing spikes with single point mutations, and subjected it to pooled sera from vaccinated hosts, thereby identifying multiple mutations that independently affect neutralization potency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These data might help to predict antigenic features of novel viral variants carrying these mutations and support the development of broad monoclonal antibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1288794","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T05:09:20Z","timestamp":1699852160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera"],"prefix":"10.3389","volume":"14","author":[{"given":"Maeva","family":"Katzmarzyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Christine","family":"Clesle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Garritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"\u010ci\u010din-\u0160ain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05644-7","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Cao","year":"2023","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1130539","article-title":"SARS-CoV-2 Omicron variants: Burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines","volume":"14","author":"Pather","year":"2023","journal-title":"Front Immunol"},{"key":"B3","article-title":"Establishment of the 2nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern","author":"Bentley","year":"2022","journal-title":"World Health Organization"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00266-4","article-title":"WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: Call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2022","journal-title":"Lancet Microbe"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1038\/s41467-022-33911-8","article-title":"Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways","volume":"13","author":"Iwata-Yoshikawa","year":"2022","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/v15020271","article-title":"TMPRSS2 is essential for SARS-CoV-2 beta and omicron infection","volume":"15","author":"Metzdorf","year":"2023","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.1c01451","article-title":"Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance","volume":"62","author":"Chen","year":"2022","journal-title":"J Chem Inf Model"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.31.474653","article-title":"The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein","author":"Peacock","year":"2022","journal-title":"bioRxiv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.22.2200396","article-title":"SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany 2021 to 2022","volume":"27","author":"Sievers","year":"2022","journal-title":"Eurosurveillance"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33614-0","article-title":"Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa","volume":"13","author":"Wolter","year":"2022","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.31219\/osf.io\/f7txy","volume-title":"Omicron variant of SARS-CoV-2 harbors a unique insertion mutation of putative viral or human genomic origin","author":"Venkatakrishnan","year":"2021"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants","volume":"386","author":"Yu","year":"2022","journal-title":"New Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0203","article-title":"Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines","volume":"377","author":"Bowen","year":"2022","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27601","article-title":"Emergence of Omicron third lineage BA.3 and its importance","volume":"94","author":"Desingu","year":"2022","journal-title":"J Med Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101757","article-title":"Post-vaccination neutralization responses to omicron sub-variants","volume":"10","author":"Jacobsen","year":"2022","journal-title":"Vaccines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2022.10.19.512891","article-title":"Distinct neutralizing antibody escape of SARS-CoV-2 omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2","author":"Qu","year":"2022","journal-title":"bioRxiv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100759","article-title":"Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection","volume":"33","author":"Chen","year":"2023","journal-title":"Lancet Regional Health - Western Pacific"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00278-5","article-title":"Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant","volume":"23","author":"Yamasoba","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-023-00584-6","article-title":"Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Discov"},{"key":"B23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00422-4","article-title":"Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00591-6","article-title":"Lung cell entry, cell\u2013cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00693-4","article-title":"The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00224-9","article-title":"Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100356","article-title":"Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells","volume":"2","author":"Becker","year":"2021","journal-title":"STAR Protoc"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.chom.2022.07.006","article-title":"Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2","volume":"30","author":"Pastorio","year":"2022","journal-title":"Cell Host Microbe"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00644-8","article-title":"Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction","volume":"32","author":"Lan","year":"2022","journal-title":"Cell Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/v14040803","article-title":"Functional analysis of spike from SARS-CoV-2 variants reveals the role of distinct mutations in neutralization potential and viral infectivity","volume":"14","author":"Kuzmina","year":"2022","journal-title":"Viruses"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2020.04.009","article-title":"Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop","volume":"432","author":"Jaimes","year":"2020","journal-title":"J Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167058","article-title":"Experimental evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants","volume":"433","author":"Laffeber","year":"2021","journal-title":"J Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110156","article-title":"Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding","volume":"37","author":"Mannar","year":"2021","journal-title":"Cell Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.immuni.2021.06.003","article-title":"Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species","volume":"54","author":"Wang","year":"2021","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","article-title":"SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.18.524660","article-title":"SARS-CoV-2 omicron XBB.1.5 may be a variant that spreads more widely and faster than other variants","author":"Sugano","year":"2023","journal-title":"bioRxiv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00010-5","article-title":"ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5","volume":"23","author":"Yue","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.21.553968","article-title":"Antibody neutralization of emerging SARS-CoV-2: EG.5.1 and XBC.1.6","author":"Wang","year":"2023","journal-title":"bioRxiv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1099\/acmi.0.000057","article-title":"Middle East respiratory coronavirus (MERS-CoV) spike (S) protein vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable alternative to the conventional neutralization assay in human seroepidemiological studies","volume":"1","author":"Lester","year":"2019","journal-title":"Access Microbiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11060994","article-title":"Evaluation of a pseudovirus neutralization assay for SARS-CoV-2 and correlation with live virus-based micro neutralization assay","volume":"11","author":"Tolah","year":"2021","journal-title":"Diagnostics"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq2427","article-title":"Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes","volume":"7","author":"Quandt","year":"2022","journal-title":"Sci Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.032","article-title":"Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: an interim report of phase 2\/3, randomized, observer-blinded, noninferiority study","volume":"40","author":"Shinkai","year":"2022","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/v15112153","article-title":"Evaluation of the neutralizing antibody STE90-C11 against SARS-CoV-2 delta infection and its recognition of other variants of concerns","volume":"15","author":"Abassi","year":"2023","journal-title":"Viruses"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1288794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T05:09:27Z","timestamp":1699852167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1288794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2023.1288794"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1288794","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.08.23295177","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"article-number":"1288794"}}